Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cognitive Impairment Associated With Schizophrenia (CIAS) – Overview
Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cognitive Impairment Associated With Schizophrenia (CIAS) – Companies Involved in Therapeutics Development
Accure Therapeutics SL
Astellas Pharma Inc
AstraZeneca Plc
Atai Life Sciences NV
Autifony Therapeutics Ltd
Biogen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Coronis NeuroSciences Ltd
Cyclerion Therapeutics Inc
EuMentis Therapeutics Inc
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Monument Therapeutics Ltd
Neurocrine Biosciences Inc
Novartis AG
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Spherium Biomed SL
Suven Life Sciences Ltd
Vanda Pharmaceuticals Inc
Cognitive Impairment Associated With Schizophrenia (CIAS) – Drug Profiles
ACT-02 – Drug Profile
Product Description
Mechanism Of Action
History of Events
ASP-5736 – Drug Profile
Product Description
Mechanism Of Action
AUT-1 – Drug Profile
Product Description
Mechanism Of Action
History of Events
AUT-6 – Drug Profile
Product Description
Mechanism Of Action
History of Events
AUT-9 – Drug Profile
Product Description
Mechanism Of Action
History of Events
AVL-3288 – Drug Profile
Product Description
Mechanism Of Action
basmisanil – Drug Profile
Product Description
Mechanism Of Action
History of Events
BI-425809 – Drug Profile
Product Description
Mechanism Of Action
History of Events
BI-474121 – Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-955829 – Drug Profile
Product Description
Mechanism Of Action
CAD-8688 – Drug Profile
Product Description
Mechanism Of Action
History of Events
CAD-9303 – Drug Profile
Product Description
Mechanism Of Action
History of Events
CP-102 – Drug Profile
Product Description
Mechanism Of Action
History of Events
CY-6463 – Drug Profile
Product Description
Mechanism Of Action
History of Events
EM-036 – Drug Profile
Product Description
Mechanism Of Action
luvadaxistat – Drug Profile
Product Description
Mechanism Of Action
History of Events
MK-4334 – Drug Profile
Product Description
Mechanism Of Action
NBI-1065846 – Drug Profile
Product Description
Mechanism Of Action
History of Events
pesampator – Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-03463275 – Drug Profile
Product Description
Mechanism Of Action
RL-007 – Drug Profile
Product Description
Mechanism Of Action
History of Events
samelisant – Drug Profile
Product Description
Mechanism Of Action
History of Events
SKL-20540 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Cognitive Impairment Associated With Schizophrenia – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit COMT for Cognitive Impairment Associated with Schizophrenia (CIAS) and Unspecified Psychiatric Disorders – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Modulate CHRM for Central Nervous System and Respiratory Disorders – Drug Profile
Product Description
Mechanism Of Action
SP-14040 – Drug Profile
Product Description
Mechanism Of Action
SUVND-4010 – Drug Profile
Product Description
Mechanism Of Action
VQW-765 – Drug Profile
Product Description
Mechanism Of Action
History of Events
VU-0467154 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects
Cognitive Impairment Associated With Schizophrenia (CIAS) – Discontinued Products
Cognitive Impairment Associated With Schizophrenia (CIAS) – Product Development Milestones
Featured News & Press Releases
Dec 14, 2021: atai Life Sciences announces successful outcome of phase 2a biomarker trial of RL-007 in cognitive impairment associated with schizophrenia
May 27, 2021: Cyclerion Therapeutics announces publication of CY6463 preclinical data in frontiers in pharmacology
May 24, 2021: Boehringer Ingelheim’s investigational treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Apr 27, 2021: Cyclerion Therapeutics hosted webinar to discuss pipeline progress, provides update on CY6463 clinical program
Apr 20, 2021: Cyclerion Therapeutics to host pipeline update webinar
Mar 02, 2021: Neurocrine Biosciences announces top-line results from phase II interact study evaluating Luvadaxistat (NBI-1065844) for the treatment of negative symptoms and cognitive impairment associated with Schizophrenia (CIAS)
Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant
Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
Apr 17, 2013: SK Biopharma Announces FDA’s Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Accure Therapeutics SL, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Atai Life Sciences NV, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Autifony Therapeutics Ltd, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Biogen Inc, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Boehringer Ingelheim International GmbH, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cyclerion Therapeutics Inc, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by EuMentis Therapeutics Inc, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Merck & Co Inc, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Monument Therapeutics Ltd, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neurocrine Biosciences Inc, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Novartis AG, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Suven Life Sciences Ltd, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, 2022
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, 2022 (Contd..1)
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022